Analyst Activity – Cowen and Company Initiates Coverage On Alder BioPharmaceuticals (NASDAQ:ALDR) With a Outperform

ME Staff
-
0

Analyst Ratings For Alder BioPharmaceuticals (NASDAQ:ALDR)

Today, Cowen and Company initiated coverage on Alder BioPharmaceuticals (NASDAQ:ALDR) with a Outperform.

There are 1 hold rating, 10 buy ratings on the stock.

The current consensus rating on Alder BioPharmaceuticals (NASDAQ:ALDR) is Buy (Score: 2.91) with a consensus target price of $33.82 per share, a potential 211.69% upside.

Some recent analyst ratings include

  • 9/26/2017-Cowen and Company initiated coverage with a Outperform rating.
  • 9/15/2017-Mizuho Reiterated Rating of Buy.
  • 9/14/2017-Royal Bank Of Canada initiated coverage with a Outperform rating.
  • 8/10/2017-Needham & Company LLC Reiterated Rating of Buy.
  • 8/9/2017-BMO Capital Markets Reiterated Rating of Outperform.
  • 7/5/2017-Aegis Reiterated Rating of Buy.

Recent Insider Trading Activity For Alder BioPharmaceuticals (NASDAQ:ALDR)
Alder BioPharmaceuticals (NASDAQ:ALDR) has insider ownership of 10.60% and institutional ownership of 76.16%.

  • On 7/18/2017 Stephen M Dow, Director, bought 25,000 with an average share price of $10.00 per share and the total transaction amounting to $250,000.00. View SEC Filing
  • On 6/20/2017 Jeffrey T L Smith, VP, sold 585 with an average share price of $20.00 per share and the total transaction amounting to $11,700.00. View SEC Filing
  • On 1/18/2017 Mark James Litton, Insider, sold 1,498 with an average share price of $23.10 per share and the total transaction amounting to $34,603.80. View SEC Filing
  • On 1/9/2017 Mark James Litton, Insider, sold 9,516 with an average share price of $23.01 per share and the total transaction amounting to $218,963.16. View SEC Filing
  • On 12/1/2016 Jeffrey T. L. Smith, VP, sold 3,000 with an average share price of $22.78 per share and the total transaction amounting to $68,340.00. View SEC Filing
  • On 12/1/2016 John A. Latham, Insider, sold 3,636 with an average share price of $22.78 per share and the total transaction amounting to $82,828.08. View SEC Filing
  • On 11/7/2016 Randall C Schatzman, CEO, sold 10,000 with an average share price of $25.16 per share and the total transaction amounting to $251,600.00. View SEC Filing

Recent Trading Activity for Alder BioPharmaceuticals (NASDAQ:ALDR)
Shares of Alder BioPharmaceuticals closed the previous trading session at with shares trading hands.